5-Azacitidine is a standard chemotherapy drug used to treat myelodysplastic syndromes (MDS) and leukemia. In this study, researchers want to determine if giving the investigational drug panobinostat with 5-azacitidine is more effective than 5-azacitidine alone for inducing remission or slowing disease progression in patients with MDS, chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).
Panobinostat is a drug called a histone deacetylase inhibitor (HDAC), which prevents cancer cells from reproducing by interfering with certain signaling pathways. Patients will be randomly assigned to receive panobinostat with 5-azacitidine or 5-azacitidine alone. 5-azacitidine is given via injection, while panobinostat is given as a capsule.